Shares of Regenxbio Inc. (NASDAQ:RGNX) have earned a consensus broker rating score of 1.13 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.

Brokerages have set a 12 month consensus price target of $30.50 for the company and are expecting that the company will post ($0.60) EPS for the current quarter, according to Zacks. Zacks has also assigned Regenxbio an industry rank of 92 out of 265 based on the ratings given to its competitors.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research cut shares of Regenxbio from a “buy” rating to a “hold” rating in a research report on Thursday, July 7th. Piper Jaffray Cos. set a $25.00 price objective on shares of Regenxbio and gave the stock a “buy” rating in a research report on Thursday, August 18th. Finally, Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research report on Monday, August 22nd.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

A number of institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors boosted its position in shares of Regenxbio by 196.1% in the second quarter. Nationwide Fund Advisors now owns 12,815 shares of the company’s stock valued at $103,000 after buying an additional 8,487 shares during the period. Metropolitan Life Insurance Co. NY purchased a new stake in Regenxbio during the second quarter valued at $136,000. Rhumbline Advisers purchased a new stake in Regenxbio during the second quarter valued at $148,000. A.R.T. Advisors LLC purchased a new stake in Regenxbio during the second quarter valued at $220,000. Finally, Strs Ohio boosted its stake in Regenxbio by 19.6% in the second quarter. Strs Ohio now owns 29,600 shares of the company’s stock valued at $236,000 after buying an additional 4,859 shares during the period. Hedge funds and other institutional investors own 68.73% of the company’s stock.

Shares of Regenxbio (NASDAQ:RGNX) traded up 5.81% during trading on Tuesday, hitting $16.03. 572,948 shares of the stock were exchanged. Regenxbio has a 52 week low of $7.07 and a 52 week high of $29.40. The stock’s market cap is $424.23 million. The firm’s 50 day moving average price is $11.90 and its 200-day moving average price is $10.90.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Regenxbio had a negative return on equity of 17.89% and a negative net margin of 451.73%. On average, analysts predict that Regenxbio will post ($2.37) EPS for the current year.

Regenxbio Company Profile

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

5 Day Chart for NASDAQ:RGNX

Get a free copy of the Zacks research report on Regenxbio (RGNX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with's FREE daily email newsletter.